Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) interaction. Some malignant tumors have responded to PD-L1/PD-1 blockade treatment strategies, and PD-L1 has been described as a potential predictive biomarker. This study discussed the expression of PD-L1 and CD8 in glioblastomas.Methods: Thirty cases of glioblastoma were stained immunohistochemically for PD-L1 and CD8, where PD-L1 expression in glioblastoma tumor tissue above 1% is considered positive and CD-8 is expressed in tumor infiltrating lymphocytes. The expression of each marker was correlated with clinicopathologic parameters. Survival analysis was conducted to correlate progression-free survival (PFS) and overall survival (OS) with PD-L1 and CD8 expression.Results: Diffuse/fibrillary PD-L1 was expressed in all cases (mean expression, 57.6%), whereas membranous PD-L1 was expressed in six of 30 cases. CD8-positive tumor-infiltrating lymphocytes (CD8+ TILs) had a median expression of 10%. PD-L1 and CD8 were positively correlated (p = .001). High PD-L1 expression was associated with worse PFS and OS (p = .026 and p = .001, respectively). Correlation of CD8+ TILs percentage with age, sex, tumor site, laterality, and outcomes were statistically insignificant. Multivariate analysis revealed that PD-L1 was the only independent factor that affected prognosis.Conclusions: PD-L1 expression in patients with glioblastoma is robust; higher PD-L1 expression is associated with lower CD8+ TIL expression and worse prognosis.
Abstract
Background: Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) interaction. Some malignant tumors have responded to PD-L1/PD-1 blockade treatment strategies, and PD-L1 has been described as a potential predictive biomarker. This study discussed the expression of PD-L1 and CD8 in glioblastomas.Methods: Thirty cases of glioblastoma were stained immunohistochemically for PD-L1 and CD8, where PD-L1 expression in glioblastoma tumor tissue above 1% is considered positive and CD-8 is expressed in tumor infiltrating lymphocytes. The expression of each marker was correlated with clinicopathologic parameters. Survival analysis was conducted to correlate progression-free survival (PFS) and overall survival (OS) with PD-L1 and CD8 expression.Results: Diffuse/fibrillary PD-L1 was expressed in all cases (mean expression, 57.6%), whereas membranous PD-L1 was expressed in six of 30 cases. CD8-positive tumor-infiltrating lymphocytes (CD8+ TILs) had a median expression of 10%. PD-L1 and CD8 were positively correlated (p = .001). High PD-L1 expression was associated with worse PFS and OS (p = .026 and p = .001, respectively). Correlation of CD8+ TILs percentage with age, sex, tumor site, laterality, and outcomes were statistically insignificant. Multivariate analysis revealed that PD-L1 was the only independent factor that affected prognosis.Conclusions: PD-L1 expression in patients with glioblastoma is robust; higher PD-L1 expression is associated with lower CD8+ TIL expression and worse prognosis.
참고문헌 (39)
- Szopa W, "Diagnostic and therapeutic biomarkers in glioblastoma : current status and future perspectives", Biomed Res Int, 2017, pp.8013575~ (2017)
- Xue S, "Relationship between expression of PD-L1and tumor angiogenesis, proliferation, and invasion in glioma", Oncotarget, 8, pp.49702~49712 (2017)
- Nduom EK, "PD-L1 expression and prognostic impact in glioblastoma", Neuro Oncol, 18, pp.195~205 (2016)
- Liu Y, "PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients", J Neurosci, 33, pp.14231~14245 (2013)
- Louis DN, "WHO classification of tumours of the central nervous system" (2016), IARC Press
- Pathology-based cancer registry 2001-2010, "Helal T", Ain Shams Faculty of Medicine, 121~ (2015)
- Cancer pathology registry:a 12 year registry 2000-2011, "Mokhtar N", National Cancer Institue, 192~208 (2011)
- Berghoff AS, "Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma", Neuro Oncol, 17, pp.1064~1075 (2015)
- Gatto F, "Systematic analysis of overall survival and interactions between tumor mutations and drug treatment", J Hematol Oncol, 9, pp.15~ (2016)
- Wainwright DA, "Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors", Clin Cancer Res, 20, pp.5290~5301 (2014)
- Wang Y, "PD-L1 expression and CD8(+)T cell infiltration predict a favorable prognosis in advanced gastric cancer", J Immunol Res, 2018, pp.4180517~ (2018)
- Carbognin L, "Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers", PLoS One, 10, pp.e0130142~ (2015)
- Larkin J, "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma", N Engl J Med, 373, pp.23~34 (2015)
- Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372, pp.2018~2028 (2015)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Taube JM, "Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape", Sci Transl Med, 4, pp.127ra37~ (2012)
- Han S, "Tumour-infiltrating CD4(+)and CD8(+)lymphocytes as predictors of clinical outcome in glioma", Br J Cancer, 110, pp.2560~2568 (2014)
- Dahlin AM, "Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor", Mod Pathol, 24, pp.671~682 (2011)
- McGranahan T, "Current state of Immunotherapy for treatment of glioblastoma", Curr Treat Options Oncol, 20, pp.24~ (2019)
- Zhu P, "Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab : a population-based study", Oncotarget, 8, pp.44015~44031 (2017)
- Sato E, "Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+", regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, 2005, pp.102, 18538~18543
- Wintterle S, "Expression of the B7-related molecule B7-H1 by glioma cells : a potential mechanism of immune paralysis", Cancer Res, 63, pp.7462~7467 (2003)
- Wilmotte R, "B7-homolog 1 expression by human glioma : a new mechanism of immune evasion", Neuroreport, 16, pp.1081~1085 (2005)
- Yao Y, "B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells", Neuro Oncol, 11, pp.757~766 (2009)
- Avril T, "Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1(PDL-1)and indoleamine 2, 3-dioxygenase(IDO)on tumour-specific T cell functions", J Neuroimmunol, 225, pp.22~33 (2010)
- Zeng J, "Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas", Oncotarget, 7, pp.8944~8955 (2016)
- Garber ST, "Immune checkpoint blockade as a potential therapeutic target : surveying CNS malignancies", Neuro Oncol, 18, pp.1357~1366 (2016)
- Yang I, "Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma : evidence of distinct immunological microenvironments that reflect tumor biology", J Neurosurg, 115, pp.505~511 (2011)
- Rutledge WC, "Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class", Clin Cancer Res, 19, pp.4951~4960 (2013)
- Mahmoud SM, "Tumor-infiltrating CD8+lymphocytes predict clinical outcome in breast cancer", J Clin Oncol, 29, pp.1949~1955 (2011)
- Ballman KV, "The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme", Neuro Oncol, 9, pp.29~38 (2007)
- Preusser M, "Clinical Neuropathology mini-review 6-2015 : PD-L1 : emerging biomarker in glioblastoma?", Clin Neuropathol, 34, pp.313~321 (2015)
- Francisco LM, "PD-L1 regulates the development, maintenance, and function of induced regulatory T cells", J Exp Med, 206, pp.3015~3029 (2009)
- Cheng X, "Structure and interactions of the human programmed cell death 1 receptor", J Biol Chem, 288, pp.11771~11785 (2013)
- Romani M, "Immune checkpoints and innovative therapies in glioblastoma", Front Oncol, 8, pp.464~ (2018)
- Kim YH, "Tumour-infiltrating T-cell subpopulations in glioblastomas", Br J Neurosurg, 26, pp.21~27 (2012)
- Heimberger AB, "Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas", Clin Cancer Res, 14, pp.5166~5172 (2008)
- Galon J, "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome", Science, 313, pp.1960~1964 (2006)
- Pages F, "In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer", J Clin Oncol, 27, pp.5944~5951 (2009)